ISSN 2149-2247 | E-ISSN 2149-2549
Invited Review
Navigating through Mutations in Acute Myeloid Leukemia. What Do We Know and What Do We Do With It?
1 Comprehensive Cancer Center and Department of Pathology, The University of Alabama at Birmingham, AL, USA  
Erciyes Med J ; : -
DOI: 10.5152/etd.2018.18136
Key Words: AML, mutations, cytogenetics, targeted therapies
Abstract

 

A clonal hematopoietic disease, acute myeloid leukemia (AML) is characterized by abnormal proliferation of early precursors of myeloid cells and blasts. It represents a heterogeneous disease group with a considerably complex biology and pathophysiology. Various translocations, chromosome copy number changes, and mutations have been described in AML, and a few of them help define the diagnosis, prognosis, and management. Cytarabine and anthracycline-based combination regimens followed by the allogeneic stem cell transplant remain the optimal treatment in most cases. However, older age and decreased tolerance to conventional therapies pose a major challenge for the conventional therapies, leading to the development of effective and less toxic therapy modalities as reviewed in this article.

 

Cite this article as:  Peker D. Navigating through Mutations in Acute Myeloid Leukemia. What Do We Know and What Do We Do with It? Erciyes Med J 2018; DOI: 10.5152/etd.2018.18136

Key Words
Authors
All
Author’s Corner
Survey
AVES | Copyright © 2018 Erciyes University Faculty of Medicine | Latest Update: 03.10.2018